---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-244659"
form_type: "8-K"
ticker: "RVTY"
cik: "0000031791"
company_name: "REVVITY, INC."
filed_at: "2021-08-12T23:59:59+00:00"
generated_at: "2026-06-29T14:03:59.583823+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PerkinElmer enters $500M delayed draw term loan to partly fund BioLegend acquisition

## Summary
- Unsecured term loan facility for $500M to fund portion of BioLegend acquisition, refinance BioLegend debt, and pay fees.
- Loan available until earlier of consummation of BioLegend acquisition or five business days after Oct 25, 2021 (possible extension to Jan 31, 2022).
- Matures on third anniversary of funding date; interest at base rate or eurocurrency rate plus spread based on debt rating.
- Concurrent $500M reduction in existing 364-day senior unsecured bridge term loan facility from Goldman Sachs.
- Covenants include debt-to-capitalization ratio (replaced by leverage/interest coverage if below investment grade) and customary events of default.

## SEC filing metadata
- accession: 0001193125-21-244659
- form_type: 8-K
- ticker: RVTY
- cik: 0000031791
- company_name: REVVITY, INC.
- filed_at: 2021-08-12T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/31791/000119312521244659/0001193125-21-244659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/31791/000119312521244659/d194876d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-244659
- JSON: https://secwatch.observer/filing/0001193125-21-244659.json
- Plain text: https://secwatch.observer/filing/0001193125-21-244659.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.